Proliferating‐cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki‐67

To investigate the prognostic value of prostatic tumour cell proliferation, as measured by Ki‐67 and proliferating cell nuclear antigen (PCNA), and to compare these measures in men at low and high risk for progression of tumour.

[1]  M. Rubenstein,et al.  An evaluation of the markers p53 and Ki‐67 for their predictive value in prostate cancer , 1998, Journal of surgical oncology.

[2]  S. Maygarden.  Applications of immunohistochemistry to the diagnosis and prognostication of prostate carcinoma and prostatic intraepithelial neoplasia. , 1994, Pathology annual.

[3]  T. H. van der Kwast,et al.  Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer. , 1989, The Journal of urology.

[4]  J. Oesterling,et al.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.

[5]  P. Abel,et al.  Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. , 1993, British journal of urology.

[6]  M. Barry,et al.  Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. , 1996, Journal of the National Cancer Institute.

[7]  S. Frizelle,et al.  Proliferative activity in benign and neoplastic prostatic epithelium , 1994, The Journal of pathology.

[8]  J. M. Mulligan,et al.  Proliferating cell nuclear antigen (PCNA) and MIB 1: Markers of locally advanced and biologically aggressive prostate cancer. , 1997, The Canadian journal of urology.

[9]  Galina Pizov,et al.  Correlation of pathologic findings with progression after radical retropubic prostatectomy , 1993, Cancer.

[10]  H. Moch,et al.  Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. , 1998, Human pathology.

[11]  D. Bostwick,et al.  Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. , 1996, The Journal of urology.

[12]  J W Moul,et al.  Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. , 1996, The Journal of urology.

[13]  P. Scardino,et al.  Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? , 1994, The Journal of urology.

[14]  E. Cooper,et al.  Tumor markers in prostate cancer , 1992, Cancer.

[15]  J. Bell,et al.  Increasing vancomycin resistance in Enterococcus spp. in Australia: Facing the challenge in the laboratory , 1997, Pathology.

[16]  D. Lubeck,et al.  Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. , 2001, The Journal of urology.

[17]  D. Slamon,et al.  Proto-oncogenes and tumor suppressor genes in human urological malignancies. , 1994, The Journal of urology.

[18]  K. Griffiths,et al.  Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters , 1992, The Prostate.

[19]  A W Partin,et al.  Disease progression following radical prostatectomy in men with Gleason score 7 tumor. , 1998, The Journal of urology.

[20]  P. Carroll,et al.  Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki‐67 and PCNA expression , 1995, The Prostate.

[21]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.

[22]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[23]  K. Gatter,et al.  Monoclonal antibody Ki‐67: its use in histopathology , 1990, Histopathology.

[24]  F. Mostofi,et al.  Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. , 1996, Surgery.

[25]  J. Kumazawa,et al.  Proliferating cell nuclear antigen in needle biopsy specimens of prostatic carcinoma. , 1994, European urology.

[26]  P. Lipponen,et al.  Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. , 1997, European urology.

[27]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[28]  A. Bergh,et al.  Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. , 1997, The Journal of urology.

[29]  H. Ozen,et al.  Determination of prognosis in patients with prostate cancer treated with radical prostatectomy: prognostic value of CD44v6 score. , 2002, The Journal of urology.

[30]  H. Idikio.  Expression of proliferating cell nuclear antigen in node-negative human prostate cancer. , 1996, Anticancer research.

[31]  J. Meyer,et al.  Cell kinetics of human tumors by in vitro bromodeoxyuridine labeling. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.